Biotechs Struggle With New Disclosure Law
Congress Passed Sarbanes-Oxley in Wake of Enron and WorldCom Corporate Accounting Scandals


Besides the typical concerns of trying to raise money, running clinical trials, and meeting regulatory requirements, many San Diego biotech leaders are learning about the tougher new reporting requirements aimed at keeping businesses honest and to regain investors' trust in public companies...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99